PDL
BioPharma Inc. (NASDAQ:PDLI) closed
at $4.95. PDL BioPharma, Inc. is engaged in the management of its antibody
humanization patents and royalty assets, which consist of the Company’s Queen
et al. patents and license agreements with several biotechnology and
pharmaceutical companies.
Poniard
Pharmaceuticals, Inc. (NASDAQ:PARD) ended at $0.620. Poniard Pharmaceuticals, Inc. is a
biopharmaceutical company focused on the development and commercialization of
cancer therapeutics. The Company’s lead product candidate is picoplatin, a new
generation platinum-based cancer therapy. Picoplatin is an intravenous
platinum-based chemotherapeutic designed to treat solid tumors that are
resistant to existing platinum-based cancer therapies.
Sunesis
Pharmaceuticals, Inc. (NASDAQ:SNSS) closed at $0.446. Sunesis Pharmaceuticals, Inc. is a
biopharmaceutical company focused on the development and commercialization of
new oncology therapeutics for the treatment of hematologic and solid tumor
cancers. The Company focuses primarily on the development of voreloxin for the
treatment of acute myeloid leukemia (AML).
Opexa
Therapeutics Inc. (NASDAQ:OPXA) ended at $2.54. Opexa Therapeutics, Inc. is a
development-stage biopharmaceutical company engaged in developing personalized
cellular therapies with the potential to treat illnesses, including multiple
sclerosis (MS). These therapies are based on the Company's T-cell technology.
Article published by Wall Street Grand. Visit the Wall Street Grand Club today. For our full disclosure please visit - http://www.wallstreetgrand.com/disclosure.html
